A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

NCT05607693 | Unknown Phase 1

• 1 other identifier: SHR3680-I-QTc
• Study Type: interventional
• Target: 52
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether daily treatment with SHR3680 affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC).

Conditions

Castration-Resistant Prostate Cancer

Outcome Measures

Primary Outcomes (2)

• Delta QTc Fridericia (QTcF)

  Mean change from baseline in QTcF as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake.

  Day -1 and Day 1 and Day 17

• Concentration-delta QTcF relationship

  Relationship between SHR3680 plasma concentration and delta QTcF based on linear-mixed effect model.

  Day -1 and Day 1 and Day 17

Secondary Outcomes (12)

• Electrocardiographic parameters Delta PR

  Day -1 and Day 1 and Day 17

• Electrocardiographic parameters Delta RR

  Day -1 and Day 1 and Day 17

• Electrocardiographic parameters Delta QRS

  Day -1 and Day 1 and Day 17

• Electrocardiographic parameters Delta QTc Bazett (QTcB)

  Day -1 and Day 1 and Day 17

• Electrocardiographic parameters T-wave morphology

  Day -1 and Day 1 and Day 17

Study Arms (1)

SHR3680

EXPERIMENTAL

Drug: SHR3680 tablets

Interventions

SHR3680 tablets DRUG

Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.

SHR3680

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male between 18 years to 75 years of age;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• Expected survival of at least 6 months;
• Histologically or cytologically confirmed adenocarcinoma of the prostate without indication of neuroendocrine or small cell features; nonmetastatic castration-resistant prostate cancer (NM-CRPC) or metastatic castration-resistant prostate cancer (mCRPC) ;
• Be surgically or medically castrated and if treated with a gonadotropin releasing hormone analog (ie, patient who has not undergone bilateral orchiectomy), then this therapy must have been initiated at least 4 weeks prior to Day 1 and must be continued throughout the study;
• Castrated level of testosterone at screening (≦ 50 ng/dL or 1.73 nmol/L);
• Organ function level must meet the following requirements (blood transfusion or hematopoietic growth factor therapy was not received within 2 weeks before blood test):
• ANC≧1.5×109/L；
• PLT≧80×109/L；
• Hb≧90 g/L；
• TBIL≦1.5×ULN；
• ALT and AST≦2.5×ULN；
• BUN and Cr≦1.5×ULN；
• GFR≧60ml/min/1.73m2；
• lead ECG: heart rate ≥ 50 beats/min, PR interval within 110-220 ms (including both ends), QTc interval corrected according to Fridericia 's criteria (QTcF) \< 470 msec. Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiography;

You may not qualify if:

• Washout period of any previous anti-tumor therapy (including radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy, androgen receptor antagonists, CYP-17 inhibitors, 5α-reductase inhibitors, estrogen, progesterone drugs, etc.) to the of the first dose of this study drug is \< 4 weeks;
• Plan to receive any other anti-tumor therapy during the treatment phase in this trial;
• Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 4 weeks;
• Known brain metastases;
• history of epilepsy, or past medical history of disease that can induce seizures (including transient ischemic attack history, cerebral stroke (except cerebral ischemic lesions only found in imaging test), brain trauma with disturbance of consciousness requiring hospitalization) within 12 months before the first dose of the study drug;
• past medical history of the following diseases within 6 months before screening: myocardial infarction, severe/unstable angina, NYHA class II-IV cardiac insufficiency, ≥ Grade 2 sustained arrhythmia (graded based on NCI CTCAE 5.0), heart failure, grade II-III atrioventricular block, complete left bundle branch block, atrial fibrillation of any grade, coronary/peripheral artery bypass graft or stenting, cerebrovascular accident (including transient ischemic attack), pulmonary embolism, deep vein thrombosis;
• Inability to swallow, chronic diarrhea and intestinal obstruction, or the presence of multiple other factors affecting drug administration and absorption;
• Patients with active HBV or HCV infection (HBV copy number ≥ 104 copies/mL, HCV copy number ≥ 103 copies/mL);
• Patients with immunodeficiency disease history (including HIV test positive, other acquired or congenital immunodeficiency diseases) or organ transplantation history;
• Patients who are unwilling to take protocol-specified contraceptive measures throughout the study treatment period and within 3 months after the last dose;
• History of significant hypersensitivity, intolerance, or allergy to any drug compound or known allergy to SHR3680 or the excipients;
• Excessive smoking (≥ 5 cigarettes/day) within 6 months before screening or smoking within 48 h before the first dose, or positive at nicotine screening test, and can't abstain from smoking during the study; History of drug abuse, positive at drug abuse screening, or history of any drug use in the past 6 months;
• History of alcoholism or regular alcohol consumption within 6 months before screening, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer with 5% alcohol or 45 mL of spirits with 40% alcohol or 150 mL of wine with 12% alcohol) or drinking within 48 h before the first dose, or positive at alcohol breath test on the day of admission, or unable to abstain during the study;
• Subjects who took any vitamins, health products or herbal medicine within 14 days before dosing;
• Subjects who took any beverage or food containing grapefruit, xanthine, caffeine, or alcohol within 48 hours before dosing; strenuous exercise; or other factors which affect drug absorption, distribution, metabolism, excretion, etc;

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

Cancer Hospital of Tianjin

Tianjin, Tianjin Municipality, 300000, China

RECRUITING

Central Study Contacts

YIKE WANG, Pharm.D

CONTACT

+86-134-0862-8814; yike.wang@hengrui.com

Shaorong Li, Ph.D

CONTACT

+86-180-0162-4511; shaorong.li@hengrui.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Multiple dose of SHR3680 will be administered

Study Record Dates

• First Submitted: October 12, 2022
• First Posted: November 7, 2022
• Study Start: April 26, 2023
• Primary Completion: November 5, 2024
• Study Completion: November 5, 2024
• Last Updated: May 15, 2023

Record last verified: 2023-05

Locations

CN (1)